This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Blue-Chip Stocks Ready to Boost Dividends


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Big pharma has been an oasis for dividend investors, and $133 billion pharmaceutical firm Merck (MRK - Get Report) is no exception. Already in 2012, shares of Merck are up 17% -- and that's on top of the firm's quarterly dividend payout. The firm currently pays out a 42-cent dividend, generating a 3.8% dividend yield at current price levels.

Merck is a diversified pharmaceutical firm that develops and markets drug therapies and vaccines worldwide. The firm acquired Schering-Plough in 2009, dramatically expanding its late-stage pipeline and growing its consumer products exposure. But like most of its major peers, Merck has the black clouds of patent losses lingering over its future. That's a big part of why MRK has such a lofty yield right now.

>>5 Pharma Stocks Everyone Hates

The Schering acquisition also left Merck with heftier U.S. exposure than before: nearly half of the firm's sales come from the domestic market. And that's a very good thing right now considering the resilience of the U.S. dollar (that effectively penalizes overseas earnings) and the impact that "Obamacare" will have on pharmaceutical volumes in the next few years.

With a deep net cash position on MRK's balance sheet and significant cash generation capabilities, this stock looks primed to hike its payouts in the next quarter.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
AMTD $26.28 0.00%
FITB $14.87 0.00%
MRK $49.03 0.00%
PM $89.06 0.00%
UNP $77.20 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs